The radioprotective substances amifostine (WR-2721) and cystamine were tested in rats following their parenteral administration (i.p., i.m., and i.v.). Cystamine is more toxic than amifostine in mice as well as in rats. Amifostine was less toxic after intravenous injection. The radioprotective effects of WR-2721 (160 mg.kg-1) and cystamine (40 mg.kg-1) were not significant when they were administered parenterally 15-20 mins before lethal doses of whole body fission neutron irradiation in the thermal column of reactor VVR-S and 30-days lethality served as an integral criterion of postradiation injury to the rat body. The fission neutrons spectrum was characterized by mean energy 0.9-1.0 MeV with 30-40% fluency participation of moderate (E=0.1 MeV) neutrons. The contamination with gamma rays was 22-30%; the dose rate of whole irradiation was within 0.3 to 0.8 Gy.min-1.
amifostine; WR-2721; cystamine; radioprotective effect; fission neutrons irradiation
Ferle-Vidovic A, Petrovic D, Vidic Z, Osmak M, Kadija K: Absence of AET protection against fast neutrons: cellular effects. Radiat Environ Biophys 19:197-203, 1981.
Genes VS: Tables of significant differences between groups of observations according to quality indicators (in Russian). Meditsina, Moscow 1964.
Kuna P: Radioprotective effectivness of cystamine administered intramuscularly to mice (in Russian). Radiobiologya, 22, 1982:517-519.
Kuna P: Appearance of radioprotective effect of gammaphos (WR-2721) in mice (in Czech). Cas Lek ces 121, 1982a:912-914.
Kuna P: Duration and degree of radioprotection of WR-2721 in mice following its intraperitoneal, intramuscular and subcutaneous administration. Radiobiol Radiother (Berlin), 24, 1983:357-364.
Kuna P: Radioprotection of small intestine and spleen hemopoiesis by gammaphos (WR-2721) or cystamine in whole body gamma irradiated mice. Biologia (Bratislava), 39, 1983:273-282.
Kuna P: Chemical radioprotection (in Czech). Avicenum, Praha 1985, pp. 148. (Translated into Russian: Meditsina, Moscow 1989, pp. 190).
Kuna P, Dostal M, Neruda O, Petyrek P, Svoboda V, Resl M, Prouza Z, Hermanska J, Spurny F, Listik E, Pitterman P, Knajfl J, Simsa J, Spelda S, Podzimek F: Radioprotective effects of gammaphos (WR-2721) and cystamine in the case of whole-body irradiation of mice by fission neutrons (in Czech). Sborn lek (Praha) 90:110-116, 1988.
Kuna P, Krajcovic C: Acute toxicity and radioprotective effectiveness of gammaphos (WR-2721) in rats (in Czech). Cas Lek ces 120:776-778, 1981.
Kuna P, Neruda O, Navratil L, Matzner J, Ziskova R: Nuclear Terrorism. J Appl Biomed 1:55-59, 2003.
Kuna P, Volenec K, Vodicka I, Dostal M: Radioprotective and hemodynamic effects of WR-2721 and cystamine in rats: Time course studies. Neoplasma 30:349-357, 1983.
Langendroff H, Langendorff M, Metzner R, Monig H, Steinbach K-H, Temme W, Tumbragel G: Radiobiological investigations with fast neutrons. II. The radioprotective action of different substances on male mice. Atomkernergie 18:83-88, 1971.
Piper JR, Stringfellow CR, Elliot RD, Johnston TP: S-2-(3-aminoalkylamino)ethyl dihydrogen phosphorothioates and related compounds as potential antiiradiation agents. J Med Chem 12:236-243, 1969.
Pospisil M: Pharmacological radiation protection. In: Baumstark-Khan C et al. (eds.). Fundamentals for the assessment of risks from environmental radiation. Kluwer Academic Publishers, The Netherlands 1999, pp. 411-420.
Roth Z, Josifko M, Maly V, Trcka V: Statistical methods in experimental medicine (in Czech). Statni zdravotnicke nakladatelstvi, 1962, pp. 589.
Sedlmeier H, Metzger E, Jentzsch U, Weitzenegger E: Schutzeffekt von Aminoprolylamino-athylthiophosphat (WR-2721) bei Neutronen-, Gamma- oder Rontgenbestrahlung von Mausen. Strahlentherapie 157:685-691, 1981.
Sigdestad CP, Connor AM, Scott RM: Effect of chemical protectors on the response of the intestine to roentgen or fission neutron irradiation. Acta Radiol Ther Phys Biol 15:401-409, 1976.
Sigdestad CP, Grdina DJ, Connor AM, Hanson WR: A comparison of radioprotection from three neutron cources and 60Co by WR-2721 and WR-151327. Radiat Res 106:224-233, 1986.
Sigdestad CP, Connor AM, Sims CS: Modification of neutron-induced hematopoietic effects by chemical radioprotectors. Int J Radiat Oncol Biol Phys 22:807-811, 1992.
Suchter LM, Hensley ML, Meropol NJ, Winer EP: 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: Clinical Practice Guidelines of the American society of clinical oncology. J Clin Oncol 20:2895-2903, 2002.
Sverdlov AG: Biological effects of neutrons and chemical protection (in Russian). Nauka, Leningrad 1974, pp. 224.
Vavrova J, Rezacova M, Pejchal J. Fullerene nanoparticles and their anti-oxidative effects: a comparison to other radioprotective agents. J Appl Biomed. 10: 1-8, 2012.